Mar 25 |
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
|
Mar 7 |
Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.01
|
Mar 7 |
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
|
Mar 7 |
Earnings Scheduled For March 7, 2024
|
Mar 5 |
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
|
Feb 20 |
What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?
|
Feb 20 |
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
|
Feb 14 |
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
|
Feb 5 |
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
|
Jan 30 |
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
|